Compare Fox Corp Class B (FOX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.91B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Fox Corp Class B is far larger — about 25.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Fox Corp Class B pays a 1.04% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FOX | MRVI | |
|---|---|---|
Market Cap | $24.91B | $972.90M |
Volume | 395,394 | 4,325,710 |
Sector | Media | Health |
52-Week High | $67.76 | $9.00 |
52-Week Low | $44.39 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.27B | $1.08B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.68, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. Fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a Buy with a $84.75 price target, implying significant upside, though cash flow projections for 2026 indicate a potential net outflow.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected net cash flow deficit in 2026 and competitive pressures in the media sector. The stock presents a value opportunity with a P/E of 14.56 trading below the analyst target, yet investors should monitor execution against future earnings expectations and industry headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
